U.S. Markets open in 7 hrs 46 mins

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3200-0.0200 (-1.49%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3400
Open1.3200
Bid0.0000 x 1000
Ask0.0000 x 1800
Day's Range1.2710 - 1.3250
52 Week Range1.0900 - 2.4200
Volume261,487
Avg. Volume1,047,633
Market Cap116.544M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.2830
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
    GlobeNewswire

    Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

    Clarus Therapeutics Inc. ("Clarus") and Lipocine, Inc. (“Lipocine”) agree to resolve all outstanding claims between the companies in the on-going intellectual property litigation (U. S. District Court for the District of Delaware) and patent interference (U. S. Patent & Trademark Office; USPTO) at no cost to Clarus.NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Claru

  • Lipocine Announces Settlement With Clarus Therapeutics
    PR Newswire

    Lipocine Announces Settlement With Clarus Therapeutics

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into a global settlement and license agreement with Clarus Therapeutics Inc. ("Clarus") to resolve all outstanding claims in the on-going intellectual property litigation between the two companies as well as the on-going interference proceeding between the two companies.

  • Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
    PR Newswire

    Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below.